| Not Yet Recruiting | A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER Biliary Tract Cancer (BTC) | — | 2026-07-01 |
| Not Yet Recruiting | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer HER 2 Positive Advanced Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | 2026-07-01 |
| Not Yet Recruiting | A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTA Sarcoma of Soft Tissue | Phase 1 / Phase 2 | 2026-07-01 |
| Not Yet Recruiting | Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Can Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer | Phase 2 | 2026-07-01 |
| Not Yet Recruiting | Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain M Solid Tumors, HER2-positive Breast Cancer | Phase 2 | 2026-04-30 |
| Not Yet Recruiting | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituz Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer Hormon Receptor Positive Breast Cancer, Breast Cancer | Phase 2 | 2025-12-01 |
| Recruiting | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow A Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma | Phase 2 | 2025-06-30 |
| Recruiting | REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis NSCLC, Brain Metastases, ROS1 Gene Rearrangement | Phase 2 | 2025-06-27 |
| Withdrawn | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases Non-small Cell Lung Cancer | Phase 2 | 2025-06-01 |
| Active Not Recruiting | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer Breast Cancer, Triple Negative Breast Cancer | Phase 2 | 2025-05-29 |
| Active Not Recruiting | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Advanced Breast Cancer | Phase 1 / Phase 2 | 2025-01-17 |
| Recruiting | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | 2024-12-05 |
| Recruiting | Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor | Phase 2 | 2024-12-03 |
| Recruiting | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast C HER2-positive Breast Cancer | Phase 2 | 2024-07-22 |
| Active Not Recruiting | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2024-06-05 |
| Recruiting | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Po Breast Cancer | Phase 2 | 2024-04-01 |
| Active Not Recruiting | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult | Phase 2 | 2023-11-24 |
| Completed | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Breast Cancer, Breast Cancer, Early-Onset | Phase 2 | 2023-07-20 |
| Active Not Recruiting | PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2023-05-24 |
| Completed | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED Triple Negative Breast Cancer, Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | 2023-02-06 |
| Completed | Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer | — | 2022-07-18 |
| Withdrawn | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer Metastatic Breast Cancer, Advanced Breast Cancer, HER2-positive Breast Cancer | Phase 2 | 2022-05-15 |
| Withdrawn | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer Advanced Breast Cancer | Phase 1 / Phase 2 | 2022-03-16 |
| Completed | Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to H Early Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer | — | 2022-02-22 |
| Completed | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents Metastatic Thymic Carcinoma, Thymoma Type B3 | Phase 2 | 2021-09-21 |
| Active Not Recruiting | Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Canc Early Breast Cancer | Phase 2 | 2021-08-05 |
| Completed | ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL Breast Cancer Metastatic | Phase 2 | 2021-06-02 |
| Terminated | CB-103 Plus NSAI In Luminal Advanced Breast Cancer Advanced Breast Cancer | Phase 2 | 2021-05-06 |
| Completed | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Pati Breast Cancer | Phase 2 | 2020-10-23 |
| Completed | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer Triple Negative Breast Cancer | Phase 2 | 2020-10-08 |
| Completed | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer | Phase 2 | 2020-10-05 |
| Completed | Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) Metastatic Prostate Cancer | Phase 2 | 2020-09-02 |
| Completed | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LU Breast Cancer, Breast Cancer Metastatic | Phase 2 | 2020-06-15 |
| Completed | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases | Phase 2 | 2020-05-25 |
| Completed | Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) Penile Cancer | Phase 2 | 2020-04-28 |
| Terminated | Checkpoint Blockade in COVID-19 Pandemic COVID-19, Pneumonia, Viral | Phase 2 | 2020-04-09 |
| Completed | Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - Breast Cancer | Phase 2 | 2019-05-07 |
| Terminated | Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients Breast Cancer | Phase 2 | 2019-04-30 |
| Terminated | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer Advanced Breast Cancer | Phase 2 | 2019-04-30 |
| Completed | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) Breast Cancer, Advanced Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | 2019-04-05 |
| Terminated | A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent Breast Cancer | Phase 2 | 2018-04-17 |
| Completed | Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines Breast Cancer | Phase 2 | 2017-12-14 |
| Completed | Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC Metastatic Breast Cancer | Phase 2 | 2017-06-28 |
| Active Not Recruiting | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy Breast Cancer | Phase 2 | 2017-06-26 |
| Completed | Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients Breast Cancer Metastatic | Phase 2 | 2017-05-02 |
| Completed | Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR- Prostate Cancer | Phase 2 | 2016-12-21 |
| Completed | Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M Non-Small Cell Lung Cancer | Phase 2 | 2016-09-02 |
| Completed | Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP) Lung Cancer | — | 2016-07-01 |
| Completed | Preoperative Olaparib Endometrial Carcinoma Study (POLEN) Endometrial Carcinoma | — | 2016-02-01 |
| Completed | T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Meta Breast Cancer | Phase 1 | 2015-10-01 |
| Completed | Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer Metastatic Breast Cancer | Phase 2 | 2015-08-01 |
| Completed | Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment Breast Neoplasm, Metastasis | Phase 2 | 2013-07-01 |
| Completed | Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer H Breast Neoplasm | — | 2013-01-01 |
| Completed | POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus Carcinoma, Endometrioid, mTOR Protein | Phase 2 | 2012-05-01 |